Lonza announced an expansion of its highly potent API (HPAPI) capacity for the specific support of Antibody Drug Conjugate (ADC) payload manufacturing.
The new suites will be capable to handle a variety of highly potent products with occupational exposure levels down to 1ng/m3 and strengthen the overall bioconjugation capabilities of Lonza in Visp.
The expansion underlines the strategic position of ADCs in the Lonza Pharma & Biotech portfolio.
The company developing and producing all components of this increasingly important cancer treatment: cytotoxic payloads, antibodies and the required linkers.
The first of the two new HPAPI suites specifically supports a global biopharmaceutical partner by securing the long-term supply of highly potent ADC payloads.
The second suite will be available to other customers for similar HPAPI and payload development and manufacturing programs.
The expansion also increases Lonza’s capabilities in providing fully scalable HPAPI and ADC solutions from lab to commercialization, which supports the accelerated timelines that many drug programs in this category require.
This new capability will offer further solutions for companies developing complex therapies.
The HPAPI and ADC payload expansion is expected to be completed by the end of 2019.
|Scheduled to be operational in 2019